ARCT (Arcturus Therapeutics Holdings) Tariff Resilience Score: 5/10 (As of Jun. 29, 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
54 GF Score
Price $6.82
GF Value $4.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings Tariff Resilience Score?

Arcturus Therapeutics Holdings ARCT -0.58% 54 Tariff Resilience Score is 5 as of Jun. 29, 2026. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,375 Biotechnology companies, Arcturus Therapeutics Holdings ranks better than 62.25% on this metric.

Arcturus Therapeutics Holdings has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Arcturus Therapeutics Holdings has Arcturus Therapeutics relies on global supply chains for raw materials and manufacturing. Tariffs on pharmaceuticals can impact costs, but the company can negotiate with suppliers and adjust pricing.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Arcturus Therapeutics Holdings might have Average Resilient.

Arcturus Therapeutics Holdings  (NAS:ARCT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Arcturus Therapeutics Holdings Tariff Resilience Score Related Terms

ARCT vs MDWD, UNCY, EQ: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcturus Therapeutics Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Tariff Resilience Score falls into.


ARCT
54GF Score
Arcturus Therapeutics Holdings Inc ARCT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Arcturus Therapeutics Holdings (ARCT) has a Tariff Resilience Score of 5 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #519 out of 1375 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Arcturus Therapeutics Holdings' Tariff Resilience Score too high?
Arcturus Therapeutics Holdings' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Arcturus Therapeutics Holdings' value of 5 is 25% above this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #519 out of 1375 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Tariff Resilience Score compare to MDWD and UNCY?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #519 out of 1375 companies for Tariff Resilience Score. This puts Arcturus Therapeutics Holdings in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Arcturus Therapeutics Holdings' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.82 — trading 54.6% above its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Tariff Resilience Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $6.82 is trading 54.6% above its estimated GF Value™ of $4.41. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • Tariff Resilience Score: 5
  • GF Value™: $4.41 vs. price of $6.82 (54.6% above fair value)
  • GF Score™: 54/100 with 4 warning signs
  • Industry Position: 25% above the Biotechnology median (#519 of 1375)

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score

Get the complete analysis for ARCT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.82
Price
$4.41
GF Value